前收市價 | 9.77 |
開市 | 9.77 |
買盤 | 10.03 x 400 |
賣出價 | 10.10 x 100 |
今日波幅 | 9.77 - 10.14 |
52 週波幅 | 7.51 - 12.44 |
成交量 | |
平均成交量 | 165,951 |
市值 | 463.079M |
Beta 值 (5 年,每月) | 0.73 |
市盈率 (最近 12 個月) | 27.16 |
每股盈利 (最近 12 個月) | 0.37 |
業績公佈日 | 2024年4月25日 - 2024年4月29日 |
遠期股息及收益率 | 0.32 (3.18%) |
除息日 | 2024年4月09日 |
1 年預測目標價 | 12.25 |
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.